Wall Street analysts were quick to downgrade Sarepta Therapeutics (NASDAQ:SRPT) on Monday as the company suspended its revenue guidance for 2025 following a second fatality linked to Elevidys, its ...

For a broader perspective on Sarepta’s outlook, explore how other analysts view the stock. Price Action: SRPT stock is trading lower by 9.96% to $17.09 at last check Wednesday. Read Next: ...

The death of a second patient taking Sarepta Therapeutics’ controversial gene therapy for Duchenne muscular dystrophy is clouding the outlook for Sarepta, and for the gene therapy industry at large.